Recent development of targeted gene delivery systems into tumors: New avenues for cancer therapy

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 3, Issue 4, 2011, Pages 1-8

  Arora, Sandeep ^a   Sharma, Arvind ^a   Dhillon, Vipasha ^a   Kumar, Vikas ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

Gene delivery; Rexin G

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BIOPOLYMER; CHITOSAN; GANCICLOVIR; GEMCITABINE; HERPESVIRUS VECTOR; LENTIVIRUS VECTOR; LIPOPLEX; LIPOSOME; PARVOVIRUS VECTOR; PEPTIDE; RETROVIRUS VECTOR; REXIN G; THYMIDINE KINASE; UNCLASSIFIED DRUG;

CANCER GENE THERAPY; COLORECTAL CANCER; CYTOTOXICITY; DRUG APPROVAL; DRUG DOSE ESCALATION; GENE MUTATION; GENETIC TRANSFECTION; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; MACROPHAGE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE; OSTEOSARCOMA; PANCREAS CANCER; PATHOGENICITY; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; STEM CELL; SUICIDE GENE THERAPY; T LYMPHOCYTE; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

EID: 80054861696     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Collines SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther 2008: 866-78.
2. Chowdhury EH. Nuclear targeting of viral and non-viral DNA. Expert Opin Drug Deliv 2009;6:697-703.
3. Chen Y, Huang L. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv 2008;5:1301-11.
4. Collines SA, Guinn BA, Harrison PT, Scallan MF, and O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther 2008: 866-78.
5. Punj V, Saint-Dic D, Daghfal S, Kanwar JR. Microbial-based therapy of cancer: a new twist to age old practice. Cancer Biol Ther 2004;3:708-14
6. www.epeiusbiotech.com
7. http://www.wiley.com/uk/genetherapy/clinical.
8. Moolten FL, Vonderhaar BK, Mroz PJ. Transduction of the herpes thymidine kinase gene into premalignant murine mammary epithelial cells renders subsequent breast cancers responsive to ganciclovir therapy. Hum Gene Ther 1996; 7:1197-204.
9. Agard C, Ligeza C, Dupas B, et al. Immune-dependent distant bystandereffect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene Ther 2001; 8: 128-36.
10. Brannon-Peppas, L. and Blanchette, J.O. (2004) Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56, 1649-1659.
11. Abou-Jawde, R. et al. (2003) An overview of targeted treatments in cancer. Clin. Ther. 25, 2121-2137.
12. Q. Li, M.A. Kay, M. Finegold, L.D. Stratford-Perricaudet, S.L. Woo, Assessment of recombinant adenoviral vectors for hepatic gene therapy, Hum. Gene Ther. 4 (1993) 403-409.
13. B. Quantin, L.D. Perricaudet, S. Tajbakhsh, J.L. Mandel, Adenovirus as an expression vector in muscle cells in vivo, Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 2581-2584.
14. B. Quantin, L.D. Perricaudet, S. Tajbakhsh, J.L. Mandel, Adenovirus as an expression vector in muscle cells in vivo, Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 2581-2584.
15. IF. Engelhardt, X. Ye, B. Doranz, J.M. Wilson, Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver, Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 6196-6200.
16. K.J. Harrington, C. Spitzweg, A.R. Bateman, J.C. Morris, R.G. Vile, Gene therapy for prostate cancer: current status and future prospects, J. Urol. 166 (2001) 1220-1233.
17. T.J. Kelly Jr., Adenovirus DNA replication, in: HS Ginsberg (Ed.), The Adenoviruses, Plenum, New York, 1984, pp. 271-308.
18. S.G. Swisher, J.A. Roth, R. Komaki, J. Gu, J.J. Lee, M. Hicks, J.Y. Ro, W.K. Hong, J.A. Merritt, K. Ahrar, N.E. Atkinson, A.M. Correa, M. Dolormente, L. Dreiling, A.K. El-Naggar, F. Fossella, R. Francisco, B. Glisson, S. Grammer, R. Herbst, A. Huaringa, B. Kemp, F.R. Khuri, J.M. Kurie, Z. Liao, T.J. McDonnell, R. Morice, F. Morello, R. Munden, V. Papadimitrakopoulou, K.M. Pisters, J.B. Putnam Jr., A.J. Sarabia, T. Shelton, C. Stevens, D.M. Shin, W.R. Smythe, A.A. Vaporciyan, G.L. Walsh, M. Yin, Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy, Clin. Cancer Res. 9 (2003) 93-101.
19. Roy, L. Holle, W. Song, E Holle, T. Wagner, X. Yu, Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro, Anticancer Res. 22 (2002) 3185-3189.
20. S.C. Anderson, D.E. Johnson, H. Engler, W. Hancock, W. Huang, K.N. Wills, R.J. Gregory, S. Sutjipto, S.F. Wen, S. Lofgren, H.M. Shepard, D.C. Maneval, p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of recombinant adenovirus, Clin. Cancer. Res. 4 (1998) 1649-1659.
21. T. Ragot, N. Vincent, P. Chafey, E. Vigne, H. Gilgenkrantz, D. Couton, J. Cartaud, P. Briand, J.C. Kaplan, M. Perricaudet, A. Khan, Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice, Nature 361 (1993) 647-650.
22. C.A. Mack, W.R. Song, H. Carpenter, T.J. Wickham, I. Kovesdi, B.G. Harvey, C.J. Magovern, O.W. Isom, T. Rosengart, E. Falck-Pedersen, N.R. Hackett, R.G. Crystal, A. Mastrangeli, Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype, Hum. Gene Ther. 8 (1997) 99-109.
23. Y. Yang, F.A. Nunes, K. Berencsi, E.E. Furth, E. Gonczol, J.M. Wilson, Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy, Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4407-4411.
24. J.L. Bramson, M. Hitt, J. Gauldie, F.L. Graham, Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination, Gene Ther. 4 (1997) 1069-1076.
25. S.E. Raper, M. Yudkoff, N. Chirmule, G.P. Gao, F. Nunes, Z.J. Haskal, E.E. Furth, K.J. Propert, M.B. Robinson, S. Magosin, H. Simoes, L. Speicher, J. Hughes, J. Tazelaar, N.A. Wivel, J.M. Wilson, M.L. Batshaw, A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency, Hum. Gene Ther. 13 (2002) 163-175.
26. M.T. Vlachaki, A. Hernandez-Garcia, M. Ittmann, M. Chhikara, L.K. Aguilar, X. Zhu, B.S. Teh, E.B. Butler, S. Woo, T.C. Thompson, H. Barrera-Saldana, E. Aguilar-Cordova, B.S. The, Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model, Mol. Ther. 6 (2002) 342-348.
27. C. Heise, T. Hermiston, L. Johnson, G. Brooks, A. Sampson-Johannes, A. Williams, L. Hawkins, D. Kirn, An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy, Nat. Med. 6 (2000) 1134-1139
28. R. Rodriguez, E.R. Schuur, H.Y. Lim, G.A. Henderson, J.W. Simons, D.R. Henderson, Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells, Cancer Res. 57 (1997) 2559-2563.
29. J.R. Bischoff, D.H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J.A. Nye, A. Sampson-Johannes, A. Fattaey, F. McCormick, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells, Science 274 (1996) 373-376.
30. Yang, C.T. et al. (2005) Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res. 25, 2049-2054
31. Laquerre, S. et al. (1998) Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J. Virol. 72, 9683-9697
32. Reinblatt, M. et al. (2005) Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann. Surg. Oncol. 12, 1025-1036.
33. Pin, R.H. et al. (2004) Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. J. Gastrointest. Surg. 8, 812-822
34. Mullen, J.T. et al. (2004) Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer 101, 869-877.
35. Wei. C. M, Gibson M, Spear P. G, Scolnick E. M, Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J. Virol. 39 (1981) 935-944.
36. Shimotohno. K, Temin H. M, Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus, Cell 26 (1981) 67-77.
37. Barzon L, Bonagur R, Castagliuolo I, Chilosi M, Franchin E, Vecchio C. Del, Giarettal, Boscaro M, Palu G, Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur. J. Endocrinol. 148 (2003) 73-80.
38. Saudemont A, Buffenoir G, Denys A, Desreumaux P, Jouy N, Hetuin D, Bauters F, Fenaux P, Quesnel B, Gene transfer of CD154 and 1L12 cDNA induces an anti-leukemic immunity in a murine model of acute leukaemia. Leukemia 16 (2002) 1637-1644
39. Caruso M, Pham-Nguyen K, Kwong Y. L, Xu B, Kosai K. I, Finegold M, Woo S. L, Chen S. H, Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma, Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11302-11306.
40. Fillat C, Carrio M, Cascante A, Sangro B, Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application, Curr. Gene Ther. 3 (2003) 13-26.
41. Dubowchik G. M, Walker M. A, Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs, Pharmacol. Ther. 83 (1999) 67-123.
42. Lewis P. F, Emerman M, Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus, J. Virol. 68 (1994) 510-516.
43. Miller D. G, Adam M. A, Miller A. D, Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection, Mol. Cell Biol. 10 (1994) 4239-4242 (1990).
44. Buchschacher Jr. G. L, Wong-Staal F, Development of lentiviral vectors for gene therapy for human diseases, Blood 95 (2000) 2499-2504.
45. Indraccolo S, Habeler W, Tisato V, Stievano L, Piovan E, Tosello V, Esposito G, Wagner R, Uberla K, Chieco-Bianchi L, Amadori A, Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors, Cancer Res. 62 (2002) 6099-6107.
46. Pang S, Kang M. K, Kung S, Yu D, Lee A, Poon B, Chen I.S. Y, Lindemann B, Park N, Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr, Clin. Cancer Res. 7 (2001) 3567-3573.
47. Solly S. K, Trajcevski S, Frisen C, Holzer G. W, Nelson E, Clerc B, Abordo-Adesida E, Castro M, Lowenstein P, Klatzmann D, Replicative retroviral vectors for cancer gene therapy, Cancer Gene Ther. 10 (2003) 30-39.
48. Logg C. R, Logg A, Matusik R. J, Bochner B. H, Kasahara N, Tissue-specific transcriptional targeting of a replicationcompetent retroviral vector, J. Virol. 76 (2002) 12783-12791.
49. Lenz HJ, Anderson WF, Hall FL, Clinical protocol. Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver. Gordon EM HUM GENE THER 2002 13 12 1515-1537.
50. Gordon EM, Chen ZH, Liu L, Whitley M, Liu L, Wei D, Groshen S, Hinton DR, Anderson WF, Beart RW, Hall FL, Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. HUM GENE THER 2001 12 2 193-204
51. www.epeiusbiotech.com
52. Gordon EM, Cornelio GH, Lorenzo CC, Levy LJP, Reed RA, Liu L, Hall FL, First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. INTJ ONCOL 2004 24 1 177-185.
53. Mulder, W.J. et al. (2005) MR molecular imaging and lfuorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 19, 2008-2010
54. Pattillo, C.B. et al. (2005) Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm. Res. 22, 1117-1120
55. Hynes, R. (2002) A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8, 918-921.
56. Schiffelers, R.M. et al. (2003) Anti-tumor efficacy of tumor vasculaturetargeted liposomal doxorubicin. J. Control. Release 91,115-122
57. Wiethoff, C.M. et al. (2001) The potential role of proteoglycans incationic lipid-mediated gene delivery. Studies of the interaction of cationic lipid-DNA complexes with model glycosaminoglycans. J. Biol. Chem. 276, 32806-32813
58. Liu, Y. et al. (1997) Factors influencing the efficiency of cationic liposomemediated intravenous gene delivery. Nat. Biotechnol. 15,167173
59. Hattori, Y. and Maitani, Y. (2005) Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther. 12, 796-80
60. Van Zanten, J. et al. (2004) A nonviral carrier for targeted gene delivery to tumor cells. Cancer Gene Ther. 11, 156-164
61. Xu, L. et al. (2002) Systemic tumor-targeted gene delivery by antitransferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 1, 337-346
62. Dutour, A. et al. (2005) Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol. Ther. 11, 311-319
63. Eichhorn, M.E. et al. (2004) Protamine enhances uptake of cationic liposomes in angiogenic microvessels. Angiogenesis 7, 133-141
64. Mori, A. et al. (2000) Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther. 7,1027-1033
65. Stuart, D.D. and Allen, T.M. (2000) A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim. Biophys. Acta 1463, 219-229
66. Pastorino, F. et al. (2004) Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications. Ann. N. Y. Acad. Sci. 1028, 90-103
67. Bartsch, M. et al. (2004) Stabilized lipid coated lipoplexes for the delivery of antisense oligonucleotides to liver endothelial cells in vitro and in vivo. J. Drug Target. 12, 613-621
68. Wagner, E. et al. (1992) Coupling of adenovirus to transferrinpolylysine/ DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc. Natl. Acad. Sci. U.S. A. 89, 6099-6103.
69. Boussif, O. et al. (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92, 7297-7301.
70. Kichler, A. et al. (1999) Polye-thyleniminies: a family of potent polymers for nucleic delivery. In Nonviral vectors for gene therapy (Hung, M.-C., Huang, L. and Wagner, E., eds), pp. 191-206, Academic Press.
71. Gautam, A. et al. (2002) Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther. 9, 28-36.
72. Schiffelers, R.M. et al. (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149
73. Pfeifer, A. and Verma, I.M. (2001) Gene therapy: promises and problems. Annu. Rev. Genomics Hum. Genet. 2, 177-211
74. Roni, V. et al. (2003) Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. Exp. Cell Res. 287, 28-38.
75. Ojeifo, J.O. et al. (1995) Angiogenesis-directed implantation ofgenetically modified endothelial cells in mice. Cancer Res. 55, 2240-2244.
76. Kershaw, M.H. et al. (2000) Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. Hum. Gene Ther. 11, 2445-2452
77. Niederman, T.M. et al. (2002) Antitumor activity of cytotoxic Tlymphocytes engineered to target vascular endothelial growth factor receptors. Proc. Natl. Acad. Sci. U. S. A. 99, 7009-7014.
78. Davidoff, A.M. et al. (2001) Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res. 7, 2870-2879.
79. De Palma, M. et al. (2003) Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9, 789-795.
80. Namba, H. et al. (1998) Bystander effect-mediated therapy of experimental brain tumor by genetically engineered tumor cells. Hum. Gene Ther. 9, 5-11.
81. Pereboeva, L. and Curiel, D.T. (2004) Cellular vehicles for cancer gene therapy: current status and future potential. BioDrugs 18, 361-385.
82. Tepper, O.M. et al. (2003) Newly emerging concepts in blood vessel growth: recent discovery of endothelial progenitor cells and their function in tissue regeneration. J. Investig. Med. 51, 353-359.
83. Rafii, S. and Lyden, D. (2003) Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9, 702-712
84. Ferrari, N. et al. (2003) Bone marrow-derived, endothelial progenitorlike cells as angiogenesis-selective gene-targeting vectors. Gene Ther. 10, 647-656.
85. Thijssen, V.L. et al. (2006) Galectin-1 is essential in angiogenesis and is a target for anti-angiogenesis therapy. Proc. Natl. Acad. Sci. U. S. A. 103, 15975-15980.
86. van Beijnum, J.R. et al. (2006) Towards high-throughput functional target discovery in angiogenesis research. Trends Mol. Med. 12, 44-52.
87. Neri, D. and Bicknell, R. (2005) Tumour vascular targeting. Nat. Rev. Cancer 5, 436-446.
88. Marshall, J. (2005) The role of bevacizumab as first-line therapy for colon cancer. Semin. Oncol. 32, S43-S47.